Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16638423 | 0.88 | KMT2A (0.58) | LMNAKMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL3231330 | 0.88 | HRH1 (0.47) | LMNABCHERAD52NLRP1 | |
| SCHEMBL16638418 | 0.87 | KMT2A (0.47) | LMNAKMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL12479844 | 0.86 | CYP3A4 (0.42) | RAD52NLRP1MAPT | |
| SCHEMBL2186574 | 0.85 | HRH1 (0.55) | BCHE | |
| SCHEMBL1444926 | 0.85 | HRH1 (0.46) | BCHERAD52NLRP1 | |
| SCHEMBL13834248 | 0.84 | HRH1 (0.43) | BCHERAD52NLRP1 | |
| SCHEMBL16638442 | 0.83 | GRIN2D (0.47) | KMT2AMEN1BCHE | |
| SCHEMBL12480412 | 0.81 | HDAC1 (0.43) | BCHERAD52NLRP1 | |
| SCHEMBL3235205 | 0.78 | HRH1 (0.58) | LMNAKMT2AMEN1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2015-09-24 | — | — | US | disclosed |
| US-9006263-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | LMNA 2784/4885KMT2A 2261/4885MEN1 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.